Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase II Study of Afinitor vs. Sutent in Non-clear Cell Advanced Renal Cell Carcinoma
2010-019966-95Phase 2Completed
- Sponsor
- Duke University
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-clear cell renal cell carcinoma (nccRCC) comparing Afinitor arm with Sutent arm (2 arms). Primary endpoint: Progression-free survival rate at 6 months. Started Oct 2010; status: completed.
02
Drugs
everolimussunitinib
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on 2010-019966-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019966-95.